“Research and development expenses Research and development expenses decreased by $44,000, or 83%, in 2025 compared to 2024, reflecting our strategy to develop the Zola brand by leveraging our existing resources and minimizing new investment.”10-K · Mar 26, 2026 ↗
Arcadia Biosciences, Inc.
RKDA
Market read
Arcadia Biosciences, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 17 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
- RKDA's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if RKDA's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 17 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
- RKDA's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
- Operating margin changed +20.8 percentage points in the latest annual period.
- Net margin changed +91.4 percentage points in the latest annual period.
- Latest annual revenue changed -3.7% year over year.
- Product pipeline and R&D has repeated adverse evidence across 3 filings.
No credible peer-relative valuation comparison is available yet.
Price as of Sep 11, 2026
0.43Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
Persistent and emerging business drivers
“Arcadia expects its quarterly operating results to fluctuate widely and unpredictably for the following reasons, among others: • its significant customer concentration; • the effectiveness of its marketing and advertising efforts; • the impact of seasonality…”10-K · Mar 26, 2026 ↗
“Arcadia expects its quarterly operating results to fluctuate widely and unpredictably for the following reasons, among others: • its significant customer concentration; • the effectiveness of its marketing and advertising efforts; • the impact of seasonality…”10-K · Mar 26, 2026 ↗
“Operating expenses (income) Cost of revenues Cost of revenues increased by $135,000, or 5%, in 2025 compared to 2024 driven by a 17% increase in Zola sales, which increased product costs and freight expenses.”10-K · Mar 26, 2026 ↗
Valuation discipline
Peer-relative valuation withheld
Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:45 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for RKDA. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for RKDA. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind RKDA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
CTVACorteva, Inc.partnerMar 26, 2026 ▾
“On May 14, 2024, Arcadia sold its non-GMO Resistant Starch (“RS”) durum wheat trait to longtime partner Corteva Agriscience (“Corteva”) for total cash consideration of $4.0 million.”
BIOXFiling-linked namepartnerMay 14, 2026 ▾
“18 On March 28, 2025, Arcadia entered into an agreement with Bioceres Crop Solutions Corp.”
Depended on by
ASTHAstrana Health, Inc.competitorMar 12, 2026 ▾
“Our competitors include Conifer Health Solutions, InnovAccer, Arcadia, Lightbeam Health Solutions, and Lumeris.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
RKDA is currently a Follower in the organic co-movement group Financial & Industrial Services. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for RKDA; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.